Logo image of EUK.MI

EUKEDOS SPA (EUK.MI) Stock Fundamental Analysis

BIT:EUK - Euronext Milan - IT0004818297 - Common Stock - Currency: EUR

0.8  +0.05 (+6.67%)

Fundamental Rating

1

Taking everything into account, EUK scores 1 out of 10 in our fundamental rating. EUK was compared to 25 industry peers in the Health Care Providers & Services industry. There are concerns on the financial health of EUK while its profitability can be described as average. EUK is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

EUK had negative earnings in the past year.
EUK had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: EUK reported negative net income in multiple years.
Each year in the past 5 years EUK had a positive operating cash flow.
EUK.MI Yearly Net Income VS EBIT VS OCF VS FCFEUK.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

1.2 Ratios

EUK has a worse Return On Assets (-0.29%) than 76.00% of its industry peers.
With a Return On Equity value of -1.76%, EUK is not doing good in the industry: 80.00% of the companies in the same industry are doing better.
EUK has a Return On Invested Capital of 2.53%. This is in the lower half of the industry: EUK underperforms 68.00% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for EUK is below the industry average of 5.61%.
Industry RankSector Rank
ROA -0.29%
ROE -1.76%
ROIC 2.53%
ROA(3y)0.12%
ROA(5y)-0.11%
ROE(3y)0.54%
ROE(5y)-0.64%
ROIC(3y)2.58%
ROIC(5y)2.22%
EUK.MI Yearly ROA, ROE, ROICEUK.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2 -2 -4 -6

1.3 Margins

EUK has a better Operating Margin (10.03%) than 84.00% of its industry peers.
EUK's Operating Margin has improved in the last couple of years.
The Gross Margin of EUK (94.58%) is better than 96.00% of its industry peers.
In the last couple of years the Gross Margin of EUK has remained more or less at the same level.
Industry RankSector Rank
OM 10.03%
PM (TTM) N/A
GM 94.59%
OM growth 3Y-2.47%
OM growth 5Y3.88%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.26%
GM growth 5Y0.24%
EUK.MI Yearly Profit, Operating, Gross MarginsEUK.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

1

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so EUK is destroying value.
The number of shares outstanding for EUK remains at a similar level compared to 1 year ago.
The number of shares outstanding for EUK remains at a similar level compared to 5 years ago.
Compared to 1 year ago, EUK has an improved debt to assets ratio.
EUK.MI Yearly Shares OutstandingEUK.MI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
EUK.MI Yearly Total Debt VS Total AssetsEUK.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

EUK has an Altman-Z score of 0.34. This is a bad value and indicates that EUK is not financially healthy and even has some risk of bankruptcy.
EUK has a Altman-Z score of 0.34. This is amonst the worse of the industry: EUK underperforms 84.00% of its industry peers.
EUK has a Debt/Equity ratio of 3.11. This is a high value indicating a heavy dependency on external financing.
EUK's Debt to Equity ratio of 3.11 is on the low side compared to the rest of the industry. EUK is outperformed by 76.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.11
Debt/FCF N/A
Altman-Z 0.34
ROIC/WACC0.54
WACC4.65%
EUK.MI Yearly LT Debt VS Equity VS FCFEUK.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M 100M

2.3 Liquidity

EUK has a Current Ratio of 0.38. This is a bad value and indicates that EUK is not financially healthy enough and could expect problems in meeting its short term obligations.
EUK's Current ratio of 0.38 is on the low side compared to the rest of the industry. EUK is outperformed by 88.00% of its industry peers.
EUK has a Quick Ratio of 0.38. This is a bad value and indicates that EUK is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.38, EUK is doing worse than 88.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.38
Quick Ratio 0.38
EUK.MI Yearly Current Assets VS Current LiabilitesEUK.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for EUK have decreased strongly by -194.26% in the last year.
EUK shows a small growth in Revenue. In the last year, the Revenue has grown by 6.68%.
The Revenue has been decreasing by -0.94% on average over the past years.
EPS 1Y (TTM)-194.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-146.11%
Revenue 1Y (TTM)6.68%
Revenue growth 3Y6.09%
Revenue growth 5Y-0.94%
Sales Q2Q%6.24%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EUK.MI Yearly Revenue VS EstimatesEUK.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
EUK.MI Yearly EPS VS EstimatesEUK.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2018 2019 0.01 0.02 0.03 0.04 0.05

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EUK. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EUK.MI Price Earnings VS Forward Price EarningsEUK.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

EUK's Enterprise Value to EBITDA is on the same level as the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 9.35
EUK.MI Per share dataEUK.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

EUK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EUKEDOS SPA

BIT:EUK (7/7/2025, 7:00:00 PM)

0.8

+0.05 (+6.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners1.98%
Ins Owner ChangeN/A
Market Cap18.19M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.36
P/FCF N/A
P/OCF 1.83
P/B 0.61
P/tB 1.89
EV/EBITDA 9.35
EPS(TTM)-0.02
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)0.44
OCFY54.62%
SpS2.22
BVpS1.31
TBVpS0.42
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.29%
ROE -1.76%
ROCE 3.37%
ROIC 2.53%
ROICexc 2.6%
ROICexgc 3.01%
OM 10.03%
PM (TTM) N/A
GM 94.59%
FCFM N/A
ROA(3y)0.12%
ROA(5y)-0.11%
ROE(3y)0.54%
ROE(5y)-0.64%
ROIC(3y)2.58%
ROIC(5y)2.22%
ROICexc(3y)2.64%
ROICexc(5y)2.29%
ROICexgc(3y)3.08%
ROICexgc(5y)2.68%
ROCE(3y)3.43%
ROCE(5y)2.97%
ROICexcg growth 3Y-1.81%
ROICexcg growth 5Y0.32%
ROICexc growth 3Y-1.47%
ROICexc growth 5Y0.29%
OM growth 3Y-2.47%
OM growth 5Y3.88%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.26%
GM growth 5Y0.24%
F-Score4
Asset Turnover0.28
Health
Industry RankSector Rank
Debt/Equity 3.11
Debt/FCF N/A
Debt/EBITDA 7.67
Cap/Depr 327.21%
Cap/Sales 45.72%
Interest Coverage 250
Cash Conversion 82.01%
Profit Quality N/A
Current Ratio 0.38
Quick Ratio 0.38
Altman-Z 0.34
F-Score4
WACC4.65%
ROIC/WACC0.54
Cap/Depr(3y)160.89%
Cap/Depr(5y)115.09%
Cap/Sales(3y)22.9%
Cap/Sales(5y)16.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-194.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-146.11%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)6.68%
Revenue growth 3Y6.09%
Revenue growth 5Y-0.94%
Sales Q2Q%6.24%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-2.86%
EBIT growth 3Y3.47%
EBIT growth 5Y2.9%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-466.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.41%
OCF growth 3Y20.95%
OCF growth 5Y10.45%